Christoph Schraeder
Associate Director Immatics
At Immatics, Dr. Christoph Schräder leverages advanced proteomics and immunopeptidomics methods to characterize novel cancer-relevant pHLA targets for the development of innovative TCR-based immunotherapies. Immatics is a clinical-stage biotechnology company and the global leader in the precision targeting of PRAME. PRAME is a target expressed in more than 50 cancers and Immatics has the broadest PRAME franchise with the most PRAME indications and modalities.
Before joining Immatics, Dr. Christoph Schräder completed a Postdoctoral Fellowship at the University of Calgary (Canada) and earned his PhD from Martin Luther University Halle (Germany), where he applied structural mass spectrometry to uncover the cross-linking pattern of elastin.
Seminars
- Leveraging state-of-the-art immunopeptidomics to map and quantify the pHLA target landscape
- Combining immunopeptidomics with complementary OMICS approaches to identify and validate novel peptide targets, driving the development of TCR-based immunotherapies and beyond
- Pushing past barriers of detection and quantification of even low-abundance pHLA targets through cutting-edge technology, unlocking new therapeutic opportunities
